Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Radgocitabine - Delta-Fly Pharma

Next Previous
X
Search
Drug Profile

Radgocitabine - Delta-Fly Pharma

Alternative Names: CNDAC; DFP-10917; NS 917; TAS-109

Latest Information Update: 12 Sep 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Delta-Fly Pharma
  • Developer Delta-Fly Pharma; Nippon Shinyaku
  • Class Amines; Antineoplastics; Nitriles; Pyrimidines; Small molecules
  • Mechanism of Action DNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute myeloid leukaemia
  • No development reported Precursor cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 10 Sep 2024 Phase-I/II clinical trials in Acute myeloid leukaemia (Second-line therapy or greater, Combination therapy) in USA (IV) (NCT06382168)
  • 08 Apr 2024 The US FDA approves the protocol for phase I/II trial of DFP-10917 combined with Ventoclax in Acute myeloid leukemia
  • 08 Mar 2024 Delta Fly Pharma had submitted the protocol to FDA of the phase I/II study of DFP 10917 combined with Venetoclax (VTX) in acute myeloid leukemia

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top